WASHINGTON (dpa-AFX) - Novavax Inc. (NVAX) announced that the journal PLOS ONE published data from a preclinical study of its recombinant nanoparticle vaccine candidate against respiratory syncytial virus or RSV, demonstrating efficacy and safety in a well-established animal model.
These data indicated that the use of an RSV fusion (F) protein nanoparticle vaccine that induced high levels of specific neutralizing antibodies protected animals from both RSV replication and disease.
'The data from this preclinical model demonstrated the potential of our RSV F nanoparticle vaccine candidate to elicit the level and type of immunity required to protect humans as measured by virus neutralization activity,' said Gale Smith, PhD, Novavax' Vice President of Vaccine Development. 'Furthermore, our RSV vaccine candidate showed no sign of immunological disease enhancement which has plagued RSV vaccine development to date.'
Copyright RTT News/dpa-AFX